Peptide·plain sequence-like
Lixisenatide
ATLPC0015930
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK
Routes
- Length44 aa
- Monoisotopic mass
ATLPC0015930
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
What safety, toxicity, or tolerability evidence is attached?
Normalized for positional visualization, not a replacement for the reported modified notation.
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK
Original notation retained for interpretation and comparison.
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK
Interpretation: Evidence should be compared across compatible peptide identities and peptidoforms. A sequence-only match may not be equivalent when terminal modifications, stereochemistry, cyclization, or cross-links differ.
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKKPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
| Link | Method |
|---|
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
Modeled net charge across common formulation and assay pH checkpoints.
Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.
Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.
Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.
Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.
A280 (1 g/L) ≈ 1.13
Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 32 % | Comparable | FDA Clinical Review 4.4.3 pharmacokinetics manual extraction · human · plasma | Route: subcutaneous | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 100 L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Lixisenatide· 12.3 Pharmacokinetics · volume of distribution single · Distribution The ap... | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Serum/plasma stability and protease stability evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 7.1 Hours 25560 seconds | Comparable | LC-MS/MS · rat · Rats blood plasma | Dose/window: 1000 ng/mL · Time: incubated at 37 °C for 6, 12, 24, and 48 h · Rats blood plasma protease · In Vitro | Open |
Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.
Reviewed observations retained without being collapsed into comparable values.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 35 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lixisenatide· 12.3 Pharmacokinetics · clearance mean apparent cl f about · After multiple... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
PubMed 30041153 | Persistence Half Life | No reported alias HGEGTFTSDLSKQMEEEAV...LKNGGPSSGAPPSKKKKKKexact | 3 identity 3 evidence |
Reference link | Exposure Max Concentration | No reported alias | 0 identity 4 evidence |
Reference link | DistributionExposurePersistence Clearance, Time To Max Concentration, Volume Of Distribution | No reported alias | 0 identity 3 evidence |
PubMed 35496622 | Stability Serum Plasma Stability | No reported alias HGEGTFTSDLSKQMEEEAV...LKNGGPSSGAPPSKKKKKKexact | 1 identity 1 evidence |
Reference link | Exposure Bioavailability | No reported alias HGEGTFTSDLSKQMEEEAV...LKNGGPSSGAPPSKKKKKKexact | 1 identity 1 evidence |
Reference link | Exposure Area Under Curve | No reported alias | 0 identity 1 evidence |
Reference link | Distribution Plasma Protein Binding | No reported alias | 0 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0015930' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.
Features are shown only when a reported notation or topology record supports them.
| Confidence |
|---|
| Match |
|---|
| Open | Sequence match | experimental | 100.0% identity |
| Open | Sequence match | experimental | 100.0% identity |
| Open | Sequence match |
Grouped composition is often more interpretable than a long amino-acid list.
The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.Sequence > 30 aa — only termini and every fifth position are numbered because later turns share earlier wheel angles.
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 444.87 ng*h/L | Comparable | FDA Clinical Pharmacology Review PMR Study TDR14311 Table 7 manual extraction · human · plasma | Route: subcutaneous · Dose/window: 20 mcg repeated dosing; pediatric patients with type 2 diabetes; ADA-negative P... · Time: day 42 | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 56.9 pg/mL | Comparable | EU Clinical Trials Register PKD11475 results manual extraction · human · plasma | Route: subcutaneous · Dose/window: single 10 mcg lixisenatide; adult patients with type 2 diabetes; N=10; sampling... · Time: day 1 | Open |
| 2 | 34.3 pg/mL | Comparable | EU Clinical Trials Register PKD11475 results manual extraction · human · plasma | Route: subcutaneous · Dose/window: single 10 mcg lixisenatide; paediatric patients with type 2 diabetes; N=8; samp... · Time: day 1 | Open |
| 3 | 26 pg/mL | Comparable | EU Clinical Trials Register PKD11475 results manual extraction · human · plasma | Route: subcutaneous · Dose/window: single 5 mcg lixisenatide; adult patients with type 2 diabetes; N=10; sampling... · Time: day 1 | Open |
| 4 | 29.7 pg/mL | Comparable | EU Clinical Trials Register PKD11475 results manual extraction · human · plasma | Route: subcutaneous · Dose/window: single 5 mcg lixisenatide; paediatric patients with type 2 diabetes; N=8; sampl... · Time: day 1 | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1-3.5 hours 3600-12600 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Lixisenatide· 12.3 Pharmacokinetics · tmax median tmax range is · 12.3 Pharmacokinetics A... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 55 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: SC · 55 · Lixisenatide · exact product name match · exact or normalized match | Open |
cell monolayer
barrier evidence
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | < 0.5 Hours < 1800 seconds | Comparable | LC-HRMS · human · 1 mg/ml human SCT protein | Dose/window: 10 μM · Time: At each time point (0, 0.5, 1, 2, 4 h), 50 μL of SCts were collected from the incubation mixture · Human SCT protease · In Vitro | Open |
| 2 | < 0.5 Hours < 1800 seconds | Comparable | LC-HRMS · porcine · 1 mg/ml göttingen minipigs SCT protein | Dose/window: 10 μM · Time: At each time point (0, 0.5, 1, 2, 4 h), 50 μL of SCts were collected from the incubation mixture · Göttingen minipigs SCT protease · In Vitro | Open |
| 3 | < 0.5 Hours < 1800 seconds | Comparable | LC-HRMS · rat · 1 mg/ml SD rats SCT protein | Dose/window: 10 μM · Time: At each time point (0, 0.5, 1, 2, 4 h), 50 μL of SCts were collected from the incubation mixture · SD rats SCT protease · In Vitro | Open |
The identity reference does not expose a sequence string.
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
| 100.0% identity |
| Open | Sequence match | experimental | 100.0% identity |
| Open | Sequence match | experimental | 100.0% identity |
| Open | Sequence match | experimental | 100.0% identity |
| Open | Sequence match | experimental | 97.2% identity |
| Open | Sequence match | experimental | 97.2% identity |
| Open | Sequence match | experimental | 96.5% identity |